within Pharmacolibrary.Drugs.R_RespiratorySystem.R03D_OtherSystemicDrugsForObstructiveAirwayDiseases.R03DX09_Mepolizumab;
model Mepolizumab 
   extends Pharmacolibrary.Drugs.ATC.R.R03DX09;

  annotation(Documentation(
    info ="<html><body><p>Mepolizumab is a humanized monoclonal antibody that targets interleukin-5 (IL-5), used as an add-on maintenance treatment for severe eosinophilic asthma and hypereosinophilic syndrome. It is approved by major regulatory agencies including FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult patients with severe eosinophilic asthma; data based on population pharmacokinetic analysis from clinical trials.</p><h4>References</h4><ol><li><p>Ortega, H, et al., &amp; Cozens, S (2014). Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites. <i>Clinical pharmacology in drug development</i> 3(1) 57–62. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.60&quot;>10.1002/cpdd.60</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27128231/&quot;>https://pubmed.ncbi.nlm.nih.gov/27128231</a></p></li><li><p>Smith, DA, et al., &amp; Beerahee, M (2011). Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. <i>Clinical pharmacokinetics</i> 50(4) 215–227. DOI:<a href=&quot;https://doi.org/10.2165/11584340-000000000-00000&quot;>10.2165/11584340-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21348536/&quot;>https://pubmed.ncbi.nlm.nih.gov/21348536</a></p></li><li><p>Gupta, A, et al., &amp; Yancey, SW (2019). Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. <i>Pediatric pulmonology</i> 54(12) 1957–1967. DOI:<a href=&quot;https://doi.org/10.1002/ppul.24508&quot;>10.1002/ppul.24508</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31502421/&quot;>https://pubmed.ncbi.nlm.nih.gov/31502421</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Mepolizumab;
